logo-loader
Cellmid Ltd

Cellmid's Japanese shopping channel sale sets revenue record of $1.14 million

Advangen is the company’s wholly-owned subsidiary engaged in development and sale of first in class, best in class clinically validated anti-ageing products.

Laboratory work
Cellmid is a life sciences company

Cellmid Ltd (ASX:CDY) has set another sales record after its second sales event this financial year on Japanese television shopping channel QVC delivered revenue of $1.14 million.

This is up from $1.1 million at a similar sales event in December 2018.

These highest ever retail sales of Cellmid’s Jo-Ju® branded hair products have confirmed the brand as one of the best performers of the QVC channel.

Shares up 32%

Investors responded positively with shares up to 27 cents intra-day, a 32% increase on yesterday's close.

The company is undertaking an audit with preliminary analysis of results indicating that sales for the fourth quarter of FY19 are also at a record high of $2.45 million – the highest ever quarterly result for the company.

This is compared to the 2018 quarter four total of $1.34 million.

 

Cellmid chief executive officer Maria Halasz said: “Our recent investment in expanding our senior leadership team and building our marketing capabilities is now translating through to increased sales and new distribution partnerships.

“We enter the 2020 financial year with positive operational momentum in sales growth and e-commerce expansion across Australia, the US and Japan.”

READ: Cellmid évolis professional product range to be sold in Europe

Cellmid is now preparing to launch its new e-commerce platform for its premium product range, évolis Professional, in Japan later this month.

The company has seen a ramp-up in its online performance since the launch of the new évolis website in Australia and the US in March 2019 and is confident that this success can be replicated in Japan in 2020.

READ: Cellmid appoints new Lyramid CEO to drive clinical development of midkine assets

Cellmid recently appointed Bart Wuurman as chief executive officer of its wholly-owned subsidiary Lyramid with the aim of unlocking shareholder value by separating the consumer health and biotech business.

His mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets.

Wuurman has successfully executed biotech deals including Antisoma in the UK via a successful IPO and Lanthio Pharma in the Netherland via a trade sale.

Quick facts: Cellmid Ltd

Price: $0.22

Market: ASX
Market Cap: $17.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Ltd named herein, including the promotion by the Company of Cellmid Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cellmid Limited outlines key components for FY2020 growth strategy

Cellmid Limited (ASX:CDY) chief executive officer and managing director Maria Halasz updates Proactive Investors on the company’s key components for its FY2020 growth strategy, which includes an exciting new global product to assist ageing hair.  Cellmid is a listed company with health...

1 week, 1 day ago

2 min read